Clinical Trial Update: Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria [Phase 3]

View source ↗

Summary

A Phase 3 open-label study evaluating the response and safety of Kuvan (sapropterin dihydrochloride) in subjects with Phenylketonuria has completed, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• KUVAN (Sapropterin dihydrochloride)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Phenylketonuria | Phase 3 | Status: COMPLETED | Results posted: 2014-07-28